Efficacy and safety of extimia® (empegfilgrastim): results of a double-blind controlled phase iii study in patients with diagnosis «breast cancer» receiving myelosuppressive chemotherapy

Objectives: to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim for prevention of neutropenia in patients receiving AT (docetaxel 75 mg/m2 + doxorubicin 50 mg/m2). Methods. 135 patients with breast cancer were randomly assigned at a ratio of 1:1:1 to rec...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: P V Krivorotko, O N Burdaeva, M N Nechaeva, M A Frolova, M V Kopp, A A Abrosimova, R A Ivanov
Médium: Artigo
Jazyk:Russo
Vydáno: IP Habib O.N. 2015-06-01
Edice:Современная онкология
Témata:
breast cancer
chemotherapy
neutropenia
filgrastim
empegfilgrastim
extimia®
On-line přístup:https://modernonco.orscience.ru/1815-1434/article/view/27010
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky